Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares conducted on October 8, 2025, and filed on October 9, 2025. The Company, a foreign private issuer, executed a share repurchase through BNP Paribas SA as part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing details a specific block of share repurchases rather than comprehensive financial statements. Key metrics for the transaction on October 8, 2025, include:
- Shares Purchased: 308,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,612.00 GBp; highest price paid was 1,630.00 GBp.
- Average Price: Volume-weighted average price (VWAP) was 1,622.48 GBp.
- Trading Venues: Purchases were executed across BATE (31,161 shares), CHIX (97,673 shares), and XLON (179,166 shares).
Since the commencement of the current programme on September 30, 2025, the Company has purchased an aggregate of 2,254,000 ordinary shares.
Material Changes and Capital Structure
Following the October 8 transaction, the Company's capital structure reflects the following updates:
- Treasury Shares: The Company now holds 249,718,844 ordinary shares in treasury.
- Shares in Issue: There are 4,065,689,695 ordinary shares in issue (excluding Treasury shares).
- Voting Rights: The total number of voting rights is 4,065,689,695.
- Treasury Voting Percentage: The percentage of voting rights attributable to shares held in treasury is 6.14%.
The filing does not provide comparative financial data (revenue, profit, cash flow) for the period, as it is a transaction-specific report.
Guidance, Outlook, and Risks
The filing contains no new financial guidance or management commentary regarding operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the Company's 2024 Annual Report on Form 20-F and Q2 2025 Results. The purchase was effected pursuant to a non-discretionary agreement, indicating a structured approach to capital return.
Investor Verification Checklist
- Verify the total number of treasury shares held (249,718,844) against the latest Form 20-F or quarterly reports to confirm the 6.14% voting rights calculation.
- Confirm the remaining capacity under the existing buyback programme announced on September 30, 2025.
- Review the "Risk Factors" section of the 2024 Form 20-F and Q2 2025 results for context on the forward-looking statement disclaimer.
- Monitor subsequent filings to track the progress of the non-discretionary buyback agreement.